市場調查報告書
商品編碼
1504259
全球壓力治療市場評估:依產品、技術、應用、最終用戶、分銷管道、地區、機會、預測(2017-2031)Compression Therapy Market Assessment, By Product, By Technology, By Applications, By End-user, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F |
全球壓力治療市場規模預計將從2023年的 40.1 億美元增至2031年的 59.4 億美元,預計2024-2031年的年複合成長率為 5.03%。淋巴水腫患者數量的增加、新產品的推出、策略聯盟和合作夥伴關係以及運動傷害數量的增加支持了市場的成長。
人們越來越認識到壓力療法在有效管理和治療腿部潰瘍、靜脈曲張和淋巴水腫等各種疾病方面的好處,為市場創造有利的成長機會。醫療保健專業人員也建議對各種其他情況進行加壓治療,包括深部靜脈血栓形成高風險的患者。透過各種分銷管道增加壓力治療產品的可用性,使這些產品易於採購,為消費者帶來了便利,對市場成長產生了積極影響。
先進產品和解決方案的開發以及美國食品和藥物管理局(FDA)的批准進一步支持市場擴張。2023年 4月,Airos Medical, Inc. 的 AIROS 8P 順序壓縮治療服裝系統和設備獲得美國 FDA 510(k)許可。此次批准使 Airos 能夠提供小腿三頭肌服裝來治療腹部腫脹。這款服裝非常適合臀部、小腿、背部和腹部淋巴水腫患者。 AIROS 8P還具有升級的AC100-240V電氣功能和更大的氣泵,這使得該設備可以在全球不同地區使用,特別是為亞太和歐洲等地區的產品擴展鋪平了道路。此類開發和批准預計將幫助公司擴大和增加對全球壓力治療市場的需求。
運動傷害的增加增強了市場需求
兒童和青少年日益參與體育活動,並且由於參與這些活動增加了受傷的可能性並增加了對治療解決方案的需求,因此對壓力療法的需求也在增加。父母鼓勵兒童和青少年參與體育活動,因為他們越來越意識到體育活動帶來的許多好處,包括增強體質、性格發展、自尊和領導能力。這種參與的增加增加了對壓力療法的需求,以有效控制因運動相關損傷的發生而引起的疼痛。約翰霍普金斯大學醫學院估計,美國約有 3,000 萬名青少年和兒童參加有組織的運動,約三分之一的兒童傷害是由運動造成的。這種增加增加了對各種壓縮療法的需求,這些療法可以減少腫脹和炎症,並減少創傷周圍軟組織的內部損傷。
新產品的推出推動市場成長
隨著新產品的推出提高了消費者的舒適度,增強了提供更高功效的產品的可用性,並使公司能夠擴大客戶群,預計全球壓力治療市場將促進該市場的成長2024年 2月,專門從事非侵入性患者監測、疼痛管理和復健醫療設備銷售和製造的領先創新醫療技術公司 Zynex, Inc. 宣布推出 Zynex DynaComp Cold Compression 和 Zynex Pro Hybrid LSO。前者結合了壓力療法和冷療法來加速恢復,並且結構緊湊且便於攜帶,可以在旅途中緩解發炎、疼痛和腫脹。這使得患者能夠更快地康復並更容易恢復日常活動。這些舉措使公司能夠確保可持續成長並實現收入來源多元化,推動成長並支持市場擴張。
本報告研究和分析了全球壓力治療市場,提供市場規模和預測、市場動態、主要參與者的現狀和前景等。
Global compression therapy market is projected to witness a CAGR of 5.03% during the forecast period 2024-2031, growing from USD 4.01 billion in 2023 to USD 5.94 billion in 2031F. The growth of the market is aided by the growing cases of lymphedema, novel product launches, strategic collaborations and partnerships, and a rise in the number of sports-related injuries.
The growing awareness about the advantages of compression therapies in the effective management and treatment of various conditions, such as leg ulcers, varicose veins, and lymphedema, among others, is providing lucrative growth opportunities to the market. Healthcare professionals also recommend compression therapy for various other conditions, including those at a high risk of deep vein thrombosis. The rising availability of compression therapy products across different distribution channels enhances consumer convenience by allowing easy procurement of these products, positively influencing the growth of the market.
The development of advanced products and solutions and receipt of clearance from the U.S. Food and Drug Administration (FDA) further support the expansion of the market. In April 2023, Airos Medical, Inc. received U.S. FDA 510(k) clearance to market their AIROS 8P Sequential Compression Therapy garment system and device. This clearance allowed AIROS to provide lower truncal garments to treat abdominal swelling. The garment is ideal for patients with lymphedema in their hips, lower legs, back, and abdomen. The AIROS 8P also features upgraded 100-240 VAC electrical capabilities and a larger air pump, allowing the device to be used in different regions across the globe and paving the way for the expansion of the product in regions such as Asia-Pacific and Europe, among others. Such developments and clearances are expected to aid the expansion of the companies and augment the global compression therapy market demand.
Rising Sports Injuries Bolsters Market Demand
The rising adoption of sports activities among children and teenagers propels the demand for compression therapy as participation in these activities augments the chances of injuries and boosts the requirement for treatment solutions. Due to the growing awareness about the various advantages offered by these activities in improving the physical fitness of children and teenagers while positively influencing their personal development and increasing self-esteem and leadership skills, parents are encouraging participation in these activities. This increased participation augments the requirement for compression therapy for the effective management of pain that can be caused by the occurrence of sports-related injuries. According to estimates from Johns Hopkins Medicine, approximately 30 million teenagers and children participate in organized sports in the United States and about one-third of the injuries procured during childhood are caused by sports. This increase is propelling the requirement for various compression therapies as they aid in reducing swelling and inflammation and also reduce internal injuries in the soft tissue that surrounds the external injury.
New Product Launches Boost Market Growth
Novel product launches are expected to fuel the global compression therapy market growth as they enhance consumer comfort and bolster the availability of products that offer enhanced effectiveness, allowing businesses to expand their customer base. In February 2024, Zynex, Inc., one of the leading innovative medical technology companies that specialize in the sale and manufacture of non-invasive patient monitoring, pain management, and rehabilitation medical devices, introduced Zynex DynaComp Cold Compression and Zynex Pro Hybrid LSO. The former combines compression and cold therapy to accelerate recovery time, and its portable and compact nature makes it easy to carry, providing on-the-go muscle relief from inflammation, soreness, and swelling. Thus, aiding patients in recovering faster and allowing them to restart their daily schedules with ease. Such efforts allow companies to ensure sustained growth and diversify revenue streams, propelling their growth and supporting the expansion of the market.
North America Anticipated to Account for Significant Market Share
Rising government initiatives support the growth of the market in North America, the growing prevalence of chronic diseases, new product launches, the rising number of sports-related injuries, and increasing investments in research and development activities. In November 2022, the U.S. House of Representatives passed H.R. 3630, the Lymphedema Treatment Act. This bill will improve the accessibility of medical compression garments for patients with lymphedema who rely on the products for treating their swelling. The utilization of medical compression garments aids in improving the quality of life and health of patients by reducing the requirement for hospitalization and the risk of infections, while protecting the patients from various complications. The federal law was passed in December 2022 and went into effect in January 2024 to improve the insurance coverage of prescribed compression supplies essential for treating lymphedema.
Additionally, the growing number of cases of diabetes and rising obesity in various countries in North America are further supporting the expansion of the market in the region, as such conditions often lead to circulatory issues, resulting in an increased demand for compression therapy products. According to estimates from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), approximately 11.6% of the population of the United States had diabetes in 2021.
Compression Bandages Hold Significant Global Compression Therapy Market Share
The segment's growth can be attributed to the expansion of the geriatric population and rising cases of diabetes, varicose veins, and foot ulcers in various regions across the globe. According to the estimates of the International Diabetes Federation (IDF), by 2045, approximately 783 million individuals will be living with diabetes. Compression bandages are the gold standard for treating underlying venous insufficiency and managing venous leg ulceration.
Furthermore, the rising studies to assess the effectiveness of compression bandaging are also providing lucrative growth opportunities to the market and supporting the segment's expansion. For instance, an observational study is being conducted to evaluate the effectiveness of compression bandaging in patients suffering from chronic edema. The CIMON sensor is developed for monitoring and placed in the calf's widest circumference, allowing it to measure the difference in capacitance. The study is expected to conclude in December 2025.
Future Market Scenario (2024-2031F)
According to the global compression therapy market analysis, the market is expected to witness significant growth in the coming years owing to rising cases of diabetes, obesity, venous ulcers, lymphedema, and varicose veins, among others. Efforts are being made to improve compression therapy so that clinicians are able to treat their patients in a time-efficient manner while enhancing their comfort. The growing availability of compression products, along with increasing cases of sports-related injuries, are also expected to offer lucrative growth opportunities to the market. The rising investments in research studies are also expected to bolster the growth of the market as these studies aid in examining and assessing the benefits offered by different compression therapies. For instance, the Massachusetts General Hospital is conducting a pilot study on compression sleeve intervention for patients that are at high risk of breast cancer-related lymphedema. The study is expected to conclude in June 2025 and will also have a compression sleeve with a sensor for capturing patient adherence to the pressure applied and compression wear.
Key Players Landscape and Outlook
Strategic collaborations and partnerships are expected to boost the global compression therapy market size in the coming years. In October 2023, MediWound Ltd. announced partnership with 3M COMPANY for phase 3 study of their leading drug candidate EscharEx, indicated for treating patients having venous leg ulcers. The company will be using two-layer compression systems Coban 2 Lite and Coban 2 by 3M during the wound healing and debridement phases of the study. The entry of the topical biologic drug developed for removing nonviable wound tissues for patients with chronic wounds into Phase 3 study is expected to happen in 2024.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work